Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis
Delamo I. Bekele, Elizabeth Cheng, Andreas Reimold, Christian Geier, Kavya Ganuthula, Jessica A. Walsh, Daniel O. Clegg, Maureen Dubreuil, Prashant Kaushik, Bernard Ng, Elizabeth Chang, Ryan Duong, Jina Park, Gail S. Kerr
Topics & Concepts
MedicineDiscontinuationAdalimumabEtanerceptInternal medicineInfliximabGolimumabCertolizumab pegolCohortPhysical therapyTNF inhibitorProportional hazards modelRheumatoid arthritisDiseaseSpondyloarthritis Studies and TreatmentsPsoriasis: Treatment and PathogenesisRheumatoid Arthritis Research and Therapies